<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597075</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 41/14 - ACTIVE-2</org_study_id>
    <secondary_id>2015-003733-10</secondary_id>
    <secondary_id>2015-003733-10</secondary_id>
    <nct_id>NCT02597075</nct_id>
  </id_info>
  <brief_title>Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy</brief_title>
  <official_title>Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy. A Multicenter Open Label Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether a structured physical activity program (PA)
      during palliative chemotherapy improves progression-free survival (PFS) and/or
      patient-reported outcomes (ESAS-r) in patients with metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While safety and feasibility as well as some improvements in fitness, fatigue and certain
      aspects of quality of life have been shown for physical activity in cancer patients during
      treatment, none of the pre-requisites above (i-iv) is fulfilled in the setting of patients
      with advanced colon cancer.

      However, evidence, primarily from the adjuvant setting, that physical activity impacts on
      treatment tolerability and tumor progression is a strong enough rationale to now embark on
      this prospective trial. By assessing in a large randomized controlled trial whether a 12-week
      structured physical activity program during chemotherapy in patients with newly diagnosed
      colorectal cancer undergoing standard first-line chemotherapy improves progression-free
      survival as compared to standard first-line chemotherapy alone, all pre-requisites for a
      practice-changing intervention are met.

      The physical exercise ACTIVE-program describes a 12-week exercise program consisting of a
      combination of a bi-weekly aerobic exercise (cycle ergometer) supervised by a physical
      therapist and a self-paced increase in physical activity during daily life using a pedometer
      with a daily step goal as a motivational tool.

      In addition to the supervised exercise program twice a week, patients of the intervention
      group are recommended to be physically active at home.

      All patients will undergo standard systemic therapy for metastatic colorectal cancer.
      Patients in the care-as-usual group are not actively encouraged to change their physical
      activity level e.g. to start a fitness program during chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2016</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>every 8 or 9 weeks during one year</time_frame>
    <description>Change between 2 tumor assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Patient-reported symptoms as measured by ESAS-r</measure>
    <time_frame>in at week 6, 12, 18, 24, 48</time_frame>
    <description>The ESAS-r is a summary score ranging from 0 to 100 with lower scores representing better quality of life of the patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>after progression (expected 1 year) lifelong follow-up</time_frame>
    <description>time from randomization to date of death. Patients without event at the time of analysis will be censored at the date they were last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Objective Response</measure>
    <time_frame>at week 8 or 9 during one year</time_frame>
    <description>best tumor response achieved during first-line systemic therapy according to RECIST criteria. Only remission status achieved during first-line therapy will be considered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selected adverse events</measure>
    <time_frame>day 1 of each cycle (every 8 or 9 weeks)</time_frame>
    <description>assessed according to NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy-completion-rate</measure>
    <time_frame>week 6, 12, 18, and 24</time_frame>
    <description>total dose in mg which was applied divided by the total dose in mg which was initially planned according to the planned chemotherapy scheme. Absolute doses of chemotherapy agents applied will be collected after each chemotherapy cycle. The total planned dose will be derived based on the planned chemotherapy scheme which is specified at baseline incorporating weight or body surface.
The chemotherapy-completion-rate is defined as the number of dose modifications due to toxicity during the first 24 weeks after randomization per patient: after each 6 week-period (week 6, 12, 18, and 24) it is assessed whether there have been dose modifications (decrease/delay of systemic treatment i.e. chemo or biological) due to toxicity during the previous 6 weeks (y/n). The proportion of patients without any dose modification due to toxicity during the first 24 weeks will be calculated as well</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation or increase of anti-hypertensive drugs</measure>
    <time_frame>day 1 of each cycle (every 8 or 9 weeks) for one year</time_frame>
    <description>In the subgroup of patients who receive bevacizumab. The proportion of patients receiving new or increased doses of anti-hypertensive drugs will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: with ST + PA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard therapy + structured Physical activity and pedometer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard therapy + physical activity program</intervention_name>
    <arm_group_label>Arm A: with ST + PA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard therapy</intervention_name>
    <arm_group_label>Arm B:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent according to ICH/GCP regulations before randomization.

          -  Patient with histologically or cytologically confirmed colorectal carcinoma (CRC) who
             start palliative first-line systemic therapy for inoperable or metastatic disease.

        Note: Patients can be included before the start or within the first three weeks of
        first-line systemic treatment.

          -  Patients with histologically or cytologically confirmed colorectal carcinoma (CRC),
             who start first-line &quot;conversion&quot;-therapy for borderline resectable metastatic disease
             and will be reassessed for metastasectomy after 3-4 months of systemic treatment.

        Note: Patients can be included before the start or within the first three weeks of
        first-line systemic treatment.

        Patients who are diagnosed with metastatic disease and were initially treated with surgery
        and/or radiochemotherapy to the primary tumor are eligible (except if all disease
        sites/metastases have been removed) Patients who have been curatively treated with
        histologically or cytologically confirmed nonmetastatic CRC previously and now relapse with
        metastatic disease are also eligible, irrespective of previous radiochemotherapy and/or
        adjuvant chemotherapy

          -  Patients must have measurable disease on CT scan or MRI to be performed within 6 weeks
             before randomization (measurability criteria according to RECIST 1.1, non-nodal
             lesions ≥10 mm, lymph nodes ≥15mm) OR evaluable disease i.e. patient with
             nonmeasurable metastases but elevated serum tumor-marker (CEA at least &gt;2xULN).

          -  Command of written and spoken language allowing for informed consent and for filling
             in trial questionnaires.

          -  Baseline patient-reported outcomes (PROs) have been completed.

          -  WHO performance status 0-2.

          -  Age ≥18 years

        Exclusion Criteria:

          -  Pre-existing severe medical conditions precluding participation in a physical activity
             program as determined by the local investigator. Such conditions include: chronic
             heart failure (greater than NYHA II), recent myocardial infarction (less than 3 months
             ago), unstable angina pectoris, clinically significant arrhythmias, uncontrolled
             hypertension with repeated systolic blood pressure above 160mmHg, and COPD (requiring
             oxygen supply or GOLD stadium greater than 2).

          -  Inability to ride a cycle ergometer e.g. for musculoskeletal reasons.

          -  Patients in whom all CRC metastases have been removed surgically. It is allowed to
             include patients for whom metastasectomy might be an option if chemotherapy induces a
             significant response.

          -  Any serious underlying medical condition (at the judgment of the investigator) which
             could impair the ability of the patient to participate in the trial (e.g. active
             autoimmune disease, uncontrolled diabetes).

          -  Concurrent treatment in a trial with experimental drugs or other anti-cancer therapy,
             which are hypothesized to alter tumor progression. Participation in an observational
             trial or a translational trial is allowed. Palliative radiotherapy is allowed.

          -  Psychiatric disorder precluding understanding of trial information, giving informed
             consent, filling out PRO forms, or interfering with compliance.

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering proper compliance with the trial protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viviane Hess, Prof Dr med</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Berset, Dr</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum der PMU Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>r.greil@salk.at</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Greil, Prof</last_name>
      <phone>+43 (6624) 482 2879</phone>
      <email>r.greil@salk.at</email>
    </contact>
    <investigator>
      <last_name>Richard Greil, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Thaler, Prof</last_name>
      <phone>+43 7242 415 3450</phone>
      <email>josef.thaler@klinikum-wegr.at</email>
    </contact>
    <investigator>
      <last_name>Josef Thaler, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tumor Zentrum Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Razvan Popescu, MD</last_name>
      <phone>+41 62 836 78 33</phone>
      <email>razvan.popescu@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Razvan Popescu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Moosmann, MD</last_name>
      <phone>41-62-838-6051</phone>
      <email>peter.moosmann@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Peter Moosmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pederiva Stefanie, MD</last_name>
      <phone>+41 56 486 34 11</phone>
      <email>stefanie.pederiva@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Stefanie Pederiva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Claraspital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Cescato, MD</last_name>
      <phone>+41 61 685 84 39</phone>
      <email>corinne.cescato@claraspital.ch</email>
    </contact>
    <investigator>
      <last_name>Corinne Cescato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Cancer Research Center at University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphael Delaloye, MD</last_name>
      <phone>+41 61 265 50 74</phone>
      <email>Raphael.delaloye@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Raphael Delaloye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana IOSI</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara De Dosso, MD</last_name>
      <phone>+41 91 811 93 02</phone>
      <email>Sara.DeDosso@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Sara De Dosso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Zweifel, MD</last_name>
      <phone>+41 32 324 36 62</phone>
      <email>martin.zweifel@szb-chb.ch</email>
    </contact>
    <investigator>
      <last_name>Martin Zweifel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Oberwallis</name>
      <address>
        <city>Brig</city>
        <zip>3900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Zenhäusern, MD</last_name>
      <phone>+41 27 604 36 60</phone>
      <email>reinhard.zenhaeusern@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Reinhard Zenhäusern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger von Moos, MD</last_name>
      <phone>+41 81 256 66 47</phone>
      <email>roger.vonmoos@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Roger von Moos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Fribourgeois HFR</name>
      <address>
        <city>Fribourg</city>
        <zip>CH-1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Küng, MD</last_name>
      <phone>+41 26 426 72 43</phone>
      <email>marc.kueng@h-fr.ch</email>
    </contact>
    <investigator>
      <last_name>Marc Küng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Genève 14</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibaud Kössler, MD</last_name>
      <phone>+41 22 372 98 62</phone>
      <email>thibaud.kossler@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Thibaud Kössler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Chimiothérapie Anti-Cancéreuse</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Bohanes, MD</last_name>
      <phone>+41 21 646 79 94</phone>
      <email>pbohanes@bluewin.ch</email>
    </contact>
    <investigator>
      <last_name>Pierre Bohanes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Wicki, MD</last_name>
      <phone>+41 61 925 27 15</phone>
      <email>andreas.wicki@ksbl.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Wicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Winterhalder, MD</last_name>
      <phone>+41 41 205 58 75</phone>
      <email>ralph.winterhalder@ksl.ch</email>
    </contact>
    <investigator>
      <last_name>Ralph Winterhalder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital Thurgau</name>
      <address>
        <city>Münsterlingen</city>
        <zip>CH-8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Inauen, MD</last_name>
      <phone>+41 71 686 29 67</phone>
      <email>roman.inauen@stgag.ch</email>
    </contact>
    <investigator>
      <last_name>Roman Inauen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Mingrone, MD</last_name>
      <phone>+41 62 311 43 47</phone>
      <email>walter.mingrone@spital.so.ch</email>
    </contact>
    <investigator>
      <last_name>Walter Mingrone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Horber, MD</last_name>
      <phone>+41 71 494 29 26</phone>
      <email>daniel.horber@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Horber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SpitalSTS AG Simmental-Thun-Saanenland</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Lüthi, MD</last_name>
      <phone>+41 58 636 26 45</phone>
      <email>jean-marc.luethi@spitalstsag.ch</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc Lüthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkozentrum - Klinik im Park</name>
      <address>
        <city>Zurich</city>
        <zip>8002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Helbling, MD</last_name>
      <phone>+41 43 344 33 33</phone>
      <email>daniel.helbling@ozh.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Helbling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Pestalozzi, Prof</last_name>
      <phone>+41 44 255 22 19</phone>
      <email>bernhard.pestalozzi@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Bernhard Pestalozzi, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Hirslanden Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas Widmer, MD</last_name>
      <phone>+41 44 387 37 80</phone>
      <email>lwidmer@onkozentrum.ch</email>
    </contact>
    <investigator>
      <last_name>Lucas Widmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Güthner, MD</last_name>
      <phone>+41 44 416 34 90</phone>
      <email>christiane.guethner@triemli.zuerich.ch</email>
    </contact>
    <investigator>
      <last_name>Christiane Güthner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>Physical Activity</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

